SWITCH - Sensing With Insulin pump Therapy to Control HbA1c
| ISRCTN | ISRCTN09806152 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN09806152 |
| ClinicalTrials.gov (NCT) | NCT00598663 |
| Protocol serial number | EUR03 |
| Sponsor | Medtronic International Trading Sarl (Switzerland) |
| Funder | Medtronic International Trading Sarl (Switzerland) |
- Submission date
- 05/12/2007
- Registration date
- 23/01/2008
- Last edited
- 28/02/2019
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Nutritional, Metabolic, Endocrine
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Plain English summary of protocol
Not provided at time of registration
Contact information
Dr Tadej Battelino
Scientific
Scientific
University Children's Hospital
Vrazov trg 1
Ljubljana
SI-1525
Slovenia
Study information
| Primary study design | Interventional |
|---|---|
| Study design | Randomised controlled two-arm cross-over multicentre trial |
| Secondary study design | Randomised cross over trial |
| Study type | Participant information sheet |
| Scientific title | Randomised, cross-over, controlled, multi-centric study to assess whether type 1 diabetic patients in sub-optimal glycaemic control can improve using the continuous glucose values of the MiniMed Paradigm REAL-Time Insulin Pump system versus the MiniMed Paradigm Insulin Pump |
| Study acronym | SWITCH |
| Study objectives | Null hypothesis: There is a 0% reduction in HbA1c from baseline compared to control group, after 6 months of treatment. |
| Ethics approval(s) | Ethics approval received from the Ljubljana Clinical Centre, Institute for Neurophysiology (Intitut za klinicno nevrofiziologijo, Klinicni center Ljubljana, Zaloka 7,1525 Ljubljana) (Slovenia) in December 2007. |
| Health condition(s) or problem(s) studied | Type 1 diabetes mellitus |
| Intervention | Treatment: Insulin pump with continuous glucose sensing Control: Insulin pump with self-monitoring blood glucose There are 2 x arms of 6 months (crossover) and a washout period between the arms of 4 months (i.e. 6 months of first treatment regimen followed by a 4-month washout, then crossed over to the other treatment for 6 months). |
| Intervention type | Other |
| Primary outcome measure(s) |
HbA1c, measured at baseline, midway and at the end of each arm. |
| Key secondary outcome measure(s) |
1. Change in glycaemic variability |
| Completion date | 01/07/2010 |
Eligibility
| Participant type(s) | Patient |
|---|---|
| Age group | Other |
| Sex | All |
| Target sample size at registration | 160 |
| Key inclusion criteria | 1. Type 1 diabetes mellitus diagnosed for at least 12 months prior to signature of informed consent 2. Patients aged 6 years to 70 years old, both male and female 3. Sub-optimal glycaemic control (7.5% less than HbA1c less than 9.5%) 4. Patient treated by continuous subcutaneous insulin infusion (CSII) for at least 6 months prior signature of informed consent 5. Patient treated within the practice of the investigator's centre at least 6 months prior to signature of informed consent 6. Patient has no preliminary experience with the sensor function of the Paradigm Real-Time (PRT)® or the Guardian® REAL-Time for the 4 months prior signature of informed consent |
| Key exclusion criteria | 1. Existing pregnancy or intention to conceive (as assessed by investigator) 2. Hearing or vision impairment so that glucose display and alarms cannot be recognised 3. Three or more incidents in the last 12 months of severe hypoglycaemia with documented blood glucose (BG) below 50 mg/dL (if possible), resulting in unconsciousness, hospitalisation or third party assistance, where recovery follows treatment with glucose or glucagon or similar 4. History of hypoglycaemic unawareness as assessed by the investigator 5. Alcohol or drug abuse, other than nicotine 6. Documented cutaneous allergy or disease (allergy to sensor or components of the sensor, psoriasis, staphylococcus, exanthema, etc.) 7. Any documented concomitant chronic disease known to affect diabetes control (e.g., altered renal function, active cancer undergoing treatment, Crohn's disease, ulcerative colitis, Addison's disease) or any concomitant pharmacological treatment that might modify glycaemic values (e.g., chronic corticosteroid therapy), eating disorders and morbid obesity (defined as adults: body mass index (BMI) greater than 35 and children BMI greater than 2 s.d. for age) as assessed by the investigator 8. Any other medical, social or psychological condition that, in the investigator's opinion, makes the patient unable to comply with the study protocol and all study procedures 9. For paediatric subjects: does not have a reliable support person 10. Plans to travel for extended periods (3+ weeks) where the devices cannot be supplied or replaced and/or medical support is limited (e.g., exotic countries, remote places) 11. Participation in another clinical study, ongoing or completed less than 3 months prior to signature of patient informed consent |
| Date of first enrolment | 01/01/2008 |
| Date of final enrolment | 01/07/2010 |
Locations
Countries of recruitment
- Austria
- Denmark
- Italy
- Luxembourg
- Netherlands
- Slovenia
- Spain
Study participating centre
University Children's Hospital
Ljubljana
SI-1525
Slovenia
SI-1525
Slovenia
Results and Publications
| Individual participant data (IPD) Intention to share | No |
|---|---|
| IPD sharing plan summary | Not provided at time of registration |
| IPD sharing plan |
Study outputs
| Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|---|---|---|---|---|---|
| Results article | results | 01/12/2012 | 28/02/2019 | Yes | No |
| Participant information sheet | Participant information sheet | 11/11/2025 | 11/11/2025 | No | Yes |
Editorial Notes
28/02/2019: Publication reference added.
20/09/2010: This record was updated to include an extended trial end date; the initial end date at the time of registration was 01/01/2010. Please also note that the database was locked on 17/09/2010.
